Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2018-04-23 Declaration of Voting R…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights' and explicitly mentions the 'Publication of total number of voting rights'. It details a capital measure (specifically 'Other capital measure' under Sec. 41 para. 1 WpHG) and provides the new total number of voting rights (31,495,785). This content directly relates to changes in the total number of shares/voting rights, which aligns with the definition of Share Issue/Capital Change (SHA). Although it is a regulatory announcement (DGAP service), the core subject matter is a capital structure update, making SHA the most specific fit over the general RNS.
2018-04-23 English
MorphoSys Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq (news with additional features)
Capital/Financing Update Classification · 98% confidence The document is a news release from MorphoSys AG dated April 18, 2018, announcing the pricing of its Initial Public Offering (IPO) of American Depositary Shares (ADSs) on Nasdaq. This announcement details the gross proceeds, the number of shares sold, the option granted to underwriters, and the expected trading date. This activity—raising capital through a public offering—falls directly under the definition of 'Capital/Financing Update'. It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it pertains to a specific financing event.
2018-04-18 English
MorphoSys Resolves a Capital Increase to Implement the Offering of 8,300,000 American Depositary Shares (ADS) in the United States
Capital/Financing Update Classification · 98% confidence The document is an 'Ad-hoc' release dated April 18, 2018, announcing that MorphoSys resolved a capital increase to implement the offering of 8,300,000 American Depositary Shares (ADS) in the United States. This action involves issuing new ordinary shares to facilitate a public offering (IPO/follow-on offering) in the US, which is a significant corporate financing activity. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it details the resolution of a capital increase for an offering, CAP is the most precise classification.
2018-04-18 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. Section 4 details the transaction involving shares by a member of the managing body. This directly corresponds to the definition of Director's Dealing (DIRS). The presence of 'DGAP-DD' further confirms this is a standard regulatory disclosure for insider transactions.
2018-04-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. Section 4 details a transaction involving a member of the managing body (Jens Holstein) regarding the acceptance of stock options. This directly corresponds to the definition of Director's Dealing (DIRS). The document is short and is a direct disclosure, not an announcement of a larger report.
2018-04-11 English
MorphoSys Nominates New Candidates for Supervisory Board (news with additional features)
Board/Management Information Classification · 100% confidence The document explicitly states that MorphoSys has published its agenda for the Annual General Meeting (AGM) and details nominations for the Supervisory Board, including retirements and new candidates. The key phrase is 'MorphoSys Nominates New Candidates for Supervisory Board' and the mention of the 'Company’s ordinary Annual General Meeting (AGM)'. This content directly relates to the governance and personnel changes discussed or voted upon at an AGM. While it mentions the AGM agenda, the core subject is the nomination of board members, which falls under Board/Management Information (MANG) or AGM Information (AGM-R). Since the announcement is about the nominations *for* the AGM and subsequent board changes, and it is a news release format, AGM-R is the most specific fit as it covers AGM-related materials, which often include board proposals. It is not a DEF 14A (Remuneration) or a DVA (Voting Results). Given the focus on board nominations tied to the upcoming AGM, AGM-R is the best classification.
2018-04-10 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.